Chinese Pharmaceutical Market 2013-2023

Date: April 9, 2013
Pages: 218
Price:
US$ 2,635.00
License [?]:
Publisher: Visiongain
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C4C29AD4E06EN
Leaflet:

Download PDF Leaflet

Chinese Pharmaceutical Market 2013-2023
Your guide to medical trends and drug revenues in China

What's the outlook for the Chinese pharma market? Can it sustain high growth? Visiongain's updated report gives you forecasted revenues there to 2023. That work also explains medical and technological trends, prospects and commercial opportunities.

Our study lets you assess sales data and detailed predictions. There, you investigate activities of domestic and international companies and assess their environment. That analysis shows you Chinese pharma's most promising and lucrative areas.

China still holds great potential for medical sales. Read on to scan crucial features of that market, find what drives it, and see what its future could be worth to healthcare industries.

Forecasts and other analyses to help you stay ahead

Our report gives you revenue forecasts to 2023, historical data, growth rates and market shares. It lets you discover quantitative and qualitative analysis, business outlooks and developments (R&D). You also gain 77 tables, 76 charts and two research interviews.

Is finding medical and sales data on China proving difficult? With our study you can stay ahead in knowledge, benefiting your research, analyses and decisions. There you find trends, innovations and opportunities for human medicines. You see what's happening.

Also, you discover future possibilities. Anyhow, the following sections show how you benefit from our new investigation and analysis.

Discover sales predictions for the Chinese market and its many submarkets

Along with revenue prediction for the overall Chinese pharma market, you see individual forecasts to 2023 for these main submarkets:
  • Hospital sales
  • Retail pharmacy sales
  • Sales via other channels
  • Conventional pharmaceuticals - with sub forecasts for novel and generic drugs
  • Biological drugs - with sub forecasts for novel and biosimilar biologics, and for vaccines
  • Traditional Chinese medicines (TCM).
Our study also gives you individual revenue forecasts to 2023 for pharma sales by therapeutic area:
  • Infectious diseases
  • Cancer
  • Cardiovascular disorders
  • Diabetes
  • Respiratory diseases
  • Autoimmune and inflammatory conditions
  • Central nervous system (CNS) disorders
  • Other medical needs (as a group).
You also see individual revenue forecasting to 2023 for these related industries in China:
  • Contract medical sales
  • Contract research - with sub forecasts for drug discovery outsourcing, and clinical trials outsourcing
  • Contract manufacturing and other domestic pharmaceutical manufacturing - with division into drug formulations, active pharma ingredients (APIs), medical devices, TCM agents, and biologicals
  • Medical devices - with sub forecasts for diagnostic imaging, consumables, orthopaedics and implanted medical devices, dental applications, and other devices.
Also, do you understand the changing market - its expanding and widening needs? There our report helps you identify potential and find opportunities for revenue growth.

Likewise, our investigation discusses what stimulates and restrains pharma businesses in China. There you find dynamics of the Chinese healthcare market and assess its potential sales, seeing what segments and products are likely to achieve the most success.

What characteristics and issues affect the Chinese pharma market?

Our report discusses issues and events affecting Chinese healthcare and related industries from 2013 onwards:
  • Epidemiological trends, including effects of industrialisation and ageing population
  • Sales outlets, distribution channels and product classes most important from 2013
  • Manufacturing and R&D, including biotechnology and trends for venture capital
  • Healthy China 2020 and other investments and reforms
  • Healthcare funding - driving and restraining forces
  • Opportunities in treating chronic diseases, including challenges of HIV and hepatitis.
That work also discusses other aspects of medical services and businesses in China, including these developments:
  • Multinationals developing cancer treatments for China - oncology R&D
  • The Anhui model
  • Investment in rural healthcare
  • Growth of contract sales activities and other pharma outsourcing (inc. off-shoring)
  • Branded generics - their prospects
  • Biosimilar manufacturers - outlooks, including developing bio-betters.
That way, you explore technological, economic, social and political (STEP) questions. You also analyse that market's strengths, weaknesses, opportunities and threats (SWOT).

Our study therefore lets you assess the potential of medical sales in China from 2013 onwards. Finding the data you need there has just got easier. See, then, what the future holds.

Leading companies - domestic and foreign - and 2016 market value

What happens next? Our report predicts the overall Chinese pharma market will reach $158bn in 2016, and expand strongly to 2023.

Our analyses show you what activities and organisations there hold high potential. The study covers these international companies and others, with ranking of the top 25:
  • Pfizer
  • Novartis
  • Sanofi
  • Merck & Co.
  • Roche
  • GlaxoSmithKline (GSK)
  • AstraZeneca
  • Johnson & Johnson.
Our work also discusses these domestic participants, and many other companies in that industry, with ranking of the top 25:
  • Sinopharm
  • Shanghai Pharma
  • Jointown Pharmaceutical
  • Nanjing Pharmaceutical
  • China National Accord Medicines.
In our study you see 290 organisations mentioned. Also, you read our interviews with other authorities on Chinese pharma - you find many opinions and discussions of crucial issues.

Prospects for product and service sales in China are strong, and from 2013 onwards there will arise many opportunities for companies. Our work shows you the technological, medical and commercial possibilities, helping you stay ahead. Discover what potential China holds.

Eight main ways Chinese Pharmaceutical Market 2013-2023 helps you

In particular then, our investigation gives you the following knowledge:
  • Revenues to 2023 for the overall pharma market in China - discover its sales prospects, seeing opportunities for domestic and multinational healthcare companies
  • Revenues to 2023 for 30 components of that market - investigate segments, finding the most promising submarkets for investments and sales
  • Discussions of leading companies in the Chinese pharma market - hear about strategies, products, capabilities, results and outlooks
  • Coverage of R&D activities - investigate healthcare research and development in that country, seeing progress and prospects
  • Interviews with authorities on Chinese pharma - discover debates and opinions to help you stay ahead
  • Competition and opportunities - see what affects that national market, learning what shapes its future, esp. prospects for developing business
  • Analysis of what stimulates and restrains the Chinese pharma industry and market - assess challenges and strengths, helping you compete and gain advantages
  • Prospects for established competitors and firms seeking to enter that healthcare sector - explore needs, practices and outlooks for future success.
You gain information found nowhere else

That work gives independent analysis. There you receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.

Our knowledge costs only a tiny fraction of potential profits from your understanding and harnessing the vast Chinese market. See its growth potential and find what you can gain.

Ordering now lets you discover those opportunities and predictions

That investigation is for everyone needing analysis of the Chinese healthcare industry and market. There you find data, trends, opportunities and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
1. EXECUTIVE SUMMARY

1.1 China: Pharmaceutical Market Review
1.2 Overview of Report Contents
1.3 Research and Analysis Methods

2. CHINESE PHARMACEUTICAL MARKET OVERVIEW, 2013-2023

2.1 China to Account for One-Third of All Industry Growth, 2013-2023
  2.1.1 China Third in the Global Market, 2013
  2.1.2 Sales Outlets in the Chinese Market: Overview, 2013
  2.1.3 Classes of Product in the Chinese Market: Overview, 2013
  2.1.4 Major Disease Areas in the Chinese Market: Overview, 2013
  2.1.5 Manufacturing and R&D in China: Overview, 2013
2.2 Key Companies and Organisations in the Chinese Market, 2013
  2.2.1 The Top 25 Domestic Chinese Companies
  2.2.2 Multinational Companies and Their Chinese Strategies
  2.2.3 Key Chinese State Bodies
2.3 A Brief History of the Chinese Pharmaceutical Industry, 1970-2013
  2.3.1 High Growth in Spite of Low Per Capita Healthcare Spending
  2.3.2 Price Inflation and Out-of-Pocket Payments
  2.3.3 Picking up the Tab
  2.3.4 Healthy China 2020: 'Unprecedented in Human History'
  2.3.5 Achievements and Potential of the Healthy China 2020 Initiative
  2.3.6 Important Developments in 2012
    2.3.6.1 Expanding the EDL
    2.3.6.2 'The Black Hole for Healthcare Funding'
    2.3.6.3 Paying for Chronic Diseases
    2.3.6.4 The Anhui Model: The Shape of Things to Come?
    2.3.6.5 Compulsory Licences: An Ominous Development?

3. RETAIL CHANNELS IN THE CHINESE MARKET 2013-2023

3.1 Hospital Sales Dominate, 2013
  3.1.1 Retail Channels in the Chinese Market: Market Projections 2013-2016
  3.1.2 Retail Channels in the Chinese Market: Market Projections 2017-2023
3.2 Sales Channel Analysis, 2013-2023
  3.2.1 Hospitals: Foundation of the Chinese Healthcare System
    3.2.1.1 Chinese Hospitals in the Era of Reform
    3.2.1.2 Market Forecast for the Hospitals Sales Channel, 2013-2023
  3.2.2 Retail Pharmacies: Central to Chinese Self-Care
    3.2.2.1 China Nepstar Prominent in a Fragmented Market
    3.2.2.2 Difficulties in Market Estimates
    3.2.2.3 Prospects for the Retail Pharmacy Sales Channel
    3.2.2.4 Market Forecast for Retail Pharmacy Market, 2013-2023
  3.2.3 Other Sales Channels: Supplying the 'Other China'
    3.2.3.1 Rural Investment to 2015
    3.2.3.2 Market Forecast for other Sales Channels, 2013-2023
3.3 Issues for Sales and Distribution in China, 2013-2023
  3.3.1 The Largest Sales Force in the World
  3.3.2 The Growth of Contract Sales in China, 2013-2023
  3.3.3 China's Fragmented Distribution Channels
  3.3.4 Problems with Fragmented Distribution Networks
  3.3.5 Consolidating Distribution: An Important Trend

4. LEADING PRODUCT CLASSES IN THE CHINESE MARKET, 2013-2023

4.1 Conventional Pharmaceuticals to Remain Key to Market, 2011-2012
  4.1.1 Product Classes in the Chinese Market: Market Projections 2013-2016
  4.1.2 Product Classes in the Chinese Market: Market Projections 2017-2023
4.2 The Market for Pharmaceuticals to Keep Growing to 2023
  4.2.1 Generics to Remain the Foundation of the Market, 2013-2023
  4.2.2 Market Structure Favours Generics
  4.2.3 Health Reforms Increase Opportunities for Branded and Generic Drugs
  4.2.4 Branded Generics: A Way Forward in China?
  4.2.5 AstraZeneca and Pfizer Leading in Branded Generics
  4.2.6 Drivers and Restraints in the Pharmaceuticals Segment, 2013
4.3 Chinese Biologics Market, 2013-2023
  4.3.1 Vaccines the Major Class of Biological Product in China, 2013-2023
  4.3.2 Roche Finding a Way Forward with Branded Biologics
  4.3.3 China Leading the Way in Biosimilars
  4.3.4 Overview of Chinese Biosimilar Manufacturers
  4.3.5 Chinese Bio-Betters?
  4.3.6 Drivers and Restraints in the Biologics Segment, 2013
4.4 Traditional Chinese Medicine, 2013-2023
  4.4.1 TCM: A Unique Phenomenon
  4.4.2 TCM Use Ubiquitous Across China
  4.4.3 Governmental Promotion of TCM
  4.4.4 Expansion of TCM
  4.4.5 Players in the TCM Field
  4.4.6 Drivers and Restraints in the TCM Field, 2013
4.4 Medical Devices, 2013-2023
  4.4.1 Breakdown of the Medical Devices Market, 2013-2023
  4.4.2 Chinese Definition of Medical Devices
  4.4.3 Importing Medical Devices
  4.4.4 Major Players in the Chinese Medical Devices Market
  4.4.5 Drivers and Restraints in the Chinese Medical Devices Market

5. LEADING THERAPEUTIC AREAS IN THE CHINESE MARKET, 2013-2023

5.1 China's Shifting Disease Burden
5.2 Disease Areas in the Chinese Market, 2013
  5.2.1 Balance Between Disease Areas, 2011-2016
  5.2.2 Balance Between Disease Areas, 2017-2023
5.3 Infectious Diseases Segment, 2013-2023
  5.3.1 Antibiotics: China's Main Medicine
  5.3.2 Curbing Antibiotics Misuse
  5.3.3 Supplying China's Genuine Antibiotics Needs
  5.3.4 Vaccinating China
  5.3.5 Fragmented Vaccines Sector
  5.3.6 Multinational Vaccine Manufacturers Eye the Market
  5.3.7 Treating China's HIV and Hepatitis Cases
  5.3.8 Drivers and Restraints for the Infectious Diseases Market, 2013
5.4 Anticancer Drug Market 2013-2023
  5.4.1 Cancer: The Price for China's Rapid Modernisation?
  5.4.2 Types of Cancer in China
  5.4.3 Targeted Therapies Gaining Ground on Chemotherapies
  5.4.4 Multinationals Tailoring Cancer Treatments for China
  5.4.5 Domestic Companies in the Oncology Space
  5.4.6 Drivers and Restraints in the Oncology Segment, 2013
5.5 Cardiovascular Segment 2013-2023
  5.5.1 China's Cardiovascular 'Pandemic'
  5.5.2 Cardiovascular Disease a Major Focus for Western Companies
  5.5.3 TCM Also Heavily Focused on Cardiovascular Treatments
  5.5.4 Medical Devices in the Cardiovascular Segment
  5.5.5 Domestic Companies in the Cardiovascular Segment
  5.5.6 Drivers and Restraints in the Cardiovascular Segment, 2013
5.6 Diabetes Segment, 2013
  5.6.1 The Largest Diabetes Market in the World
  5.6.2 A Specifically Chinese Problem?
  5.6.3 Diabetes Management in China in 2013
  5.6.4 Nordisk, Sanofi and Lilly: The Diabetes Big Three Compete for the Chinese Market
  5.6.5 Other Companies Aiming for the Diabetes Segment
  5.6.6 Drivers and Restraints in the Diabetes Segment, 2013
5.7 Respiratory Diseases Segment, 2013
  5.7.1 COPD: The Leading Killer
  5.7.2 Leading Drugs in the Market
  5.7.3 AstraZeneca Leading Respiratory Diseases Research
  5.7.4 Drivers and Restraints in the Respiratory Diseases Segment, 2013
5.8 Autoimmune/Inflammatory Diseases Segment, 2013
  5.8.1 Diagnosis Remains a Key Issue in this Segment
  5.8.2 Existing Treatment Regimens Suboptimal?
  5.8.3 Drivers and Restraints for Autoimmune/Inflammatory Diseases Segment, 2013
5.9 Central Nervous System (CNS) Diseases Market 2013-2023
  5.9.1 Ageing Population a Key Driver for CNS Disease Segment
  5.9.2 Neurodegenerative Disease Prevalence and Diagnosis Set to Rise
  5.9.3 Pain Relief a New Priority for China
  5.9.4 Depression and Anxiety Rising
  5.9.5 Drivers and Restraints in the CNS Diseases Segment, 2013
5.10 Other Disease Areas

6. CHINESE PHARMACEUTICAL MANUFACTURING, 2013-2023

6.1 'Workshop of the World': China as Pharmaceutical Manufacturing Hub
6.2 Chinese Contract Manufacturing Since the 1990s
  6.2.1 Growth of the Contract Manufacturing Market, 2013-2023
  6.2.2 Why China?
  6.2.3 Drivers and Restraints for Chinese CMOs, 2013
6.3 China's Manufacturing Output, 2013
  6.3.1 Manufacturing Output to Reach $2 Trillion by 2023
  6.3.2 Pharma Formulations: Chinese Output to 2023
    6.3.2.1 India Still Preferred for Secondary Manufacturing
  6.3.3 TCM and Related Herbal Drugs: To Become The Leading Area of 'Pharmaceutical' Output by 2023
    6.3.3.1 The 12th Five-Year Plan Favours the TCM Industry
  6.3.4 APIs: China to Retain its Dominance of Global Export Markets
    6.3.4.1 Tighter Regulation to Bring China's API Standards in Line with International Norms
  6.3.5 Biologics Manufacturing: the Fastest-Growing Area of Chinese Pharmaceutical Industry Output to 2023
    6.3.5.1 China Targeting Biomanufacturing Leadership
  6.3.6 Medical Devices Output to Record Nearly 20% CAGR to 2023
    6.3.6.1 Chinese Medical Device Manufacturers Continuing to Ascend Value Chain
6.4 Chinese Manufacturing: Conclusions

7. CHINA'S PHARMACEUTICAL R&D, 2013-2023

7.1 Chinese as Research Hub
7.2 China Research Outsourcing Market
  7.2.1 Growth of the Research Outsourcing Market, 2013-2023
  7.2.2 Clinical Trials the Foundation of Chinese Research Outsourcing
  7.2.3 More Than 3,000 Clinical Trials in China Ongoing in 2013
  7.2.4 Governmental Promotion of the Clinical Trials Sector
  7.2.5 The Growth of the Outsourced Preclinical Research Sector in China
  7.2.6 China and India to Dominate Growth in the Drug Discovery Outsourcing Market
  7.2.7 Major Overseas Players in Chinese Contract Research
  7.2.8 Major Domestic Players in Chinese Contract Research
  7.2.9 Drivers and Restraints for Research Outsourcing in China
7.3 Innovation in the Domestic Chinese Pharmaceutical Industry
  7.3.1 Domestic Drug Discovery Pipeline
  7.3.2 China's Lack of First-Class Facilities and Convincing Precedents
  7.3.3 Chinese Innovation in Biotechnology
  7.3.4 China's Genomic Sequencing Capabilities
  7.3.5 Potential Breakthroughs in Biomarkers?
  7.3.6 Chinese Regenerative Medicine
  7.3.7 Gene Therapies
  7.3.8 Stem Cells in China
  7.3.9 Stem Cell Controversies
7.4 Chinese Pharma Research: Conclusions

8. QUALITATIVE INDUSTRY ANALYSIS: DRIVERS AND RESTRAINTS, 2013

8.1 Strengths: China Has Major Healthcare Challenges and is Paying to Improve its Treatment System
  8.1.1 Domestic Disease Burden Growing With GDP
  8.1.2 The Market to Date is Underdeveloped
  8.1.3 The Government's Investment in Healthcare
8.2 Weaknesses: China is Fundamentally Unlike Other Major Pharma Markets
  8.2.1 Chinese Healthcare has Deep Systemic Challenges
  8.2.2 China's Domestic Solutions to Medical Need
  8.2.3 IP Remains an Issue, 12 Years After China Joined the WTO
8.3 Opportunities: The Scramble for China
  8.3.1 Diversifying Portfolios for China
  8.3.2 Tailoring Portfolios for the Market
  8.3.3 Building Closer Links with the Chinese Pharma Industry
8.4 Threats: A House Built on Sand?
  8.4.1 Making a Profit Under the Anhui Model
  8.4.2 Growth Via the State: Will this Work Longer Term?
  8.4.3 How Long will Outsourcing be Worthwhile?
8.5 Social Factors: Who are the Chinese People, and What Do They Want from the Pharma Industry?
  8.5.1 The Ageing Dragon
  8.5.2 The Obesity Epidemic
  8.5.3 The Effect of Social Factors on Medical Treatment in China
8.6 Technological Factors: Will China Domesticate Healthcare Technologies?
8.7 Economic Factors: Can the Chinese Miracle Continue, and What Happens to Healthcare if it Doesn't?
  8.7.1 China's Rise as an Economic Superpower
  8.7.2 What are the Underlying Problems?
  8.7.3 The Five-Year Plan, and Afterwards
8.8 Political: What Will the Chinese Government Do?

9. RESEARCH INTERVIEWS

9.1 Interview with Benjamin Shobert, Teleos Consulting
  9.1.1 Drug Revenues and the Anhui Model
  9.1.2 'Heaven is High, and the Emperor is Far Away': Government Policy in Theory and its Implementation in Practice
  9.1.3 IP and Technology Transfer in China
  9.1.4 Big Pharma Strategies in China
  9.1.5 One Country, Two Healthcare Systems?
  9.1.6 Innovation in China
  9.1.7 The Big Picture in the Next Ten Years
9.2 Interview with Justin Chakma, Thomas, McNerney & Partners
  9.2.1 Differences Between Innovation in China and in Other Emerging Markets
  9.2.2 Funding Advantages for Chinese Biotech
  9.2.3 Investment Targets for Chinese Venture Capital
  9.2.4 Dominance of Oncology in Chinese R&D
  9.2.5 Restraints on Innovation in China
  9.2.6 Important Coming Trends in Chinese R&D and Venture Capital Funding

10. CONCLUSIONS

10.1 The Chinese Pharma Market Will Continue to Greatly Outperform All Other Major Markets
10.2 The Healthcare Reforms Will Drive Major Changes in the Market
10.3 All Major Pharmaceutical Companies Looking to Expand in the Chinese Market
10.4 Generic Drugs to Remain Central to the Market
10.5 Chronic Diseases to Become Increasingly Important to the Market
10.6 China Remains the Pharma Industry's Greatest Challenge and Greatest Opportunity

LIST OF FIGURES

Figure 2.1 Chinese Pharmaceutical Market: Revenues ($bn), 2011-2023
Figure 2.2 Global Pharmaceutical Market by Region: Revenues ($bn), Market Shares (%), 2011
Figure 2.3 Sales Channels in the Chinese Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2011
Figure 2.4 Product Classes in the Chinese Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2011
Figure 2.5 Market Shares (%) of Product Classes in Chinese Market, Compared to Global Market, 2011
Figure 2.6 Market Shares (%) of Drug Product Classes in Chinese Market, Compared to Global Market, 2011
Figure 2.7 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2011
Figure 2.8 Market Shares (%) of Selected Disease Areas in Chinese Market, Compared to Global Market, 2011
Figure 2.9 Revenue Value ($bn) of Outsourced Manufacturing, Preclinical Drug Development Research, and Clinical Trials Research in China, 2011
Figure 2.10 Leading 25 Domestic Chinese Pharmaceutical Manufacturers: Market Shares (%), 2011
Figure 2.11 Market Shares (%) of Top 5, 10, 15, 20 and 25 Companies in Chinese Market, Compared to Global Market, 2011
Figure 2.12 Healthcare Spend as Percentage of GDP, Selected Leading Nations, 2010
Figure 3.1 Sales Channels in the Chinese Pharmaceutical Market: Revenues ($bn), 2011-2012
Figure 3.2 Sales Channels in the Chinese Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2016
Figure 3.3 Sales Channels in the Chinese Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2023
Figure 3.4 Sales Channels in the Chinese Pharmaceutical Market: Revenues ($bn), 2011-2023
Figure 3.5 Hospital Sales Channel: Revenue ($bn), 2011-2023
Figure 3.6 Retail Pharmacy Sales Channel: Revenue ($bn), 2011-2023
Figure 3.7 Other Sales Channels: Revenue ($bn), 2011-2023
Figure 3.8 Contract Sales in China: Revenue ($bn), 2011-2023
Figure 4.1 Product Classes in the Chinese Pharmaceutical Market: Revenues ($bn), 2011-2012
Figure 4.2 Product Classes in the Chinese Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2016
Figure 4.3 Product Classes in the Chinese Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2023
Figure 4.4 Product Classes in the Chinese Pharmaceutical Market: Revenues ($bn), 2011-2023
Figure 4.5 Chinese Pharmaceutical Market: Revenue ($bn), 2011-2023
Figure 4.6 Pharmaceuticals Segment Breakdown: Revenues ($bn), 2011-2023
Figure 4.7 Pharmaceuticals Segment Breakdown: Revenues ($bn), 2011, 2016, 2023
Figure 4.8 Drivers and Restraints for the Pharmaceuticals Segment, 2013
Figure 4.9 Biologics Segment: Revenue ($bn), 2011-2023
Figure 4.10 Biologics Segment Breakdown: Revenues ($bn), 2011-2023
Figure 4.11 Biologics Segment Breakdown: Revenues ($bn), 2011, 2016, 2023
Figure 4.12 Drivers and Restraints for the Biologics Segment, 2013
Figure 4.13 TCM Segment: Revenue ($bn), 2011-2023
Figure 4.14 Drivers and Restraints for the TCM Segment, 2013
Figure 4.15 Devices Segment: Revenue ($bn), 2011-2023
Figure 4.16 Devices Segment Breakdown: Revenues ($bn), 2011-2023
Figure 4.17 Devices Segment Breakdown: Revenues ($bn), 2011, 2016, 2023
Figure 4.18 Drivers and Restraints for the Devices Segment, 2013
Figure 5.1 Causes of Mortality in China, 2002
Figure 5.2 Disease Areas Breakdown: Revenues ($bn), 2011-2012
Figure 5.3 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2016
Figure 5.4 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2023
Figure 5.5 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), 2011-2023
Figure 5.6 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), 2011, 2016, 2023
Figure 5.7 Infectious Diseases Segment: Revenue ($bn), 2011-2023
Figure 5.8 Market Shares (%) of Antibiotic Classes in Chinese Market, Compared to Global Market, 2011
Figure 5.9 Drivers and Restraints for the Infectious Diseases Segment, 2013
Figure 5.10 Oncology Segment: Revenue ($bn), 2011-2023
Figure 5.11 Drivers and Restraints for the Oncology Segment, 2013
Figure 5.12 Cardiovascular Segment: Revenue ($bn), 2011-2023
Figure 5.13 Leading Disease Areas for TCM, Market Shares (%) 2011
Figure 5.14 Drivers and Restraints for the Cardiovascular Segment, 2013
Figure 5.15 Diabetes Segment: Revenue ($bn), 2011-2023
Figure 5.16 Drivers and Restraints for the Diabetes Segment, 2013
Figure 5.17 Respiratory Diseases Segment: Revenue ($bn), 2011-2023
Figure 5.18 Drivers and Restraints for the Respiratory Diseases Segment, 2013
Figure 5.19 Autoimmune/Inflammatory Segment: Revenue ($bn), 2011-2023
Figure 5.20 Drivers and Restraints for the Autoimmune/Inflammatory Diseases Segment, 2013
Figure 5.21 CNS Diseases Segment: Revenue ($bn), 2011-2023
Figure 5.22 Drivers and Restraints for the CNS Diseases Segment, 2013
Figure 5.23 Other Disease Areas Segment: Revenue ($bn), 2011-2023
Figure 6.1 Chinese Contract Manufacturing Market: Revenue ($bn), 2011-2023
Figure 6.2 Drivers and Restraints for Chinese Contract Manufacturing, 2013
Figure 6.3 Chinese Pharma Manufacturing by Area: Revenues ($bn), Market Shares (%) 2011
Figure 6.4 Chinese Manufacturing by Area: Revenues ($bn), 2012, 2017, 2023
Figure 7.1 Chinese Contract Research Market: Revenue ($bn), 2011-2023
Figure 7.2 Breakdown of Chinese Contract Research Market: Revenues ($bn), 2011-2012
Figure 7.3 Breakdown of Chinese Contract Research Market: Revenues ($bn), 2011-2023
Figure 7.4 Ongoing FDA-Listed Clinical Trials Wholly or Partly Conducted in China, Breakdown by Phase, Q1 2013
Figure 7.5 Drivers and Restraints for Outsourced Research in China, 2013
Figure 10.1 China's Pharmaceutical Market, Revenues ($bn), 2011-2016
Figure 10.2 China's Pharmaceutical Market, Revenues ($bn), 2017-2023
Figure 10.3 China's Pharmaceutical Market, Breakdown by Sales Channel: Revenues ($bn), 2011-2023
Figure 10.4 Projected Growth of Outsourcing Activities to China, AGR (%), 2012-2023
Figure 10.5 Market Breakdown by Product Type, Revenues ($bn), 2011-2023
Figure 10.6 Selected Disease Areas, Revenues ($bn), 2011-2023

COMPANIES LISTED

3SBIO
Abbvie (Abbott Laboratories)
Acambis
Advanced Biologics
Advexin
Agilent
Alliance Boots
Amgen
Anhui BBCA Biochemical
AppTech Laboratory Services
Asian Cancer Research Group
Astellas
AstraZeneca
Aurobindo
AutekBiom
Baxter
Bayer Healthcare
BeiGene
Beijing Bionovo Medicine Development
Beijing Four Rings
Beijing Kexing Bioproducts
Beijing Northland Biotech
Beijing Sihuan
Beijing SL Pharmaceutical
Beijing Taiyang
Beijing Tongrengtang Pharmaceutical
Beijing University
Beijung Tiantan Biological Products
BGI (formerly Beijing Genomics Institute)
Bio-Bridge Science
BiODura
BioDuraBio-pharmaceutical
Biotech Pharmaceutical
BMP Sunstone
Boehringer Ingelheim
Bristol-Myers Squibb
Broad Institute
Buchang Pharmaceutical
Cancer Foundation of China
Cancer Therapeutics
CASiGEN Pharma
Celgene
Charles River Laboratories
Chemizon (Beijing) Pharma-Tech
Chengdu Di'ao Pharmaceutical Group
Chengdu Institute of Biological Products
Chengdu Kanghong Biotech
China Aoxing
China National Accord Medicines
China National Biotec Group
China National Center for Drug Screening
China National Medicines
China Nepstar Chain Drugstore
China OTC Association
China Otsuka Pharmaceutical
China Pharmaceutical Commerce Association
China Pharmaceutical Quality Management Association
China Resources Double Crane Pharmaceutical
China Sky One Medical
ChinaGate
Chinese Academy of Medical Sciences
Chinese Academy of Sciences
Chinese Centre for Disease Control and Prevention
Chinese Diabetes Society
Chongqing Fortune Pharmaceutical
Chongqing Taiji Industry
Cipla
Cord Blood America
Covance
Crown Bioscience
Cumencor
Daiichi Sankyo
Denosim
Diapin Therapeutics
Dr. Reddy's Laboratories
Egret
Eisai
Eli Lilly
Epitomics
Excel PharmaStudies
FeRx
Frontage Laboratories
Fudan University
Fuzhou Fuxing Pharmaceutical
Gan & Lee Pharmaceutical
Gendicine
GeneScience Pharmaceuticals
Genor Biomanufacturing
Genzyme
Gilead Sciences
GlaxoSmithKline
Golden Meditech Holdings
Greater China Corporation
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Guangdong BeiKang Pharmaceutical
Guangdong Province People's Hospital
Guangzhou Institute of Biomedicine and Health
Guangzhou Medical University
Guangzhou Pharmaceutical
Guizhou Baiqiang Pharmaceutical
Hainan Litzman Pharmaceutical
Hangzhou Huadong Medicine Group
Hangzhou Jiuyuan Gene Engineering
Hangzhou Sanofi-Synthelabo Minsheng
Hangzhou Tigermed Consulting
Hangzhou Zhongmei Huadong Pharmaceutical
Harbin Pharmaceutical
HD Biosciences
Hebei Medical University
Hengrui
HitGen
Huadong Medicine
Hualan Biological Engineering
Hualida Biotech
Huazhong University of Science and Technology
Hutchison MediPharma
i3 Research
ICON
Inner Mongolia Yili Energy
Institute for BioMedical Research (Shanghai)
International Diabetes Foundation
Introgen
Isotechnika Pharma
Ivax
Jiangsu Hansen Pharmaceutical
Jiangsu Hengrui Medicine
Jiangsu New Medicine Research Institution
Jiangsu Province Hospital
Jiangsu Walvax Biotech
Johnson & Johnson
Joincare Pharma
Jointown Pharmaceutical
Kanda Biotechnology
Kangmei Pharmaceutical
Lee's Pharmaceutical
Lepu Medical
Livzon Pharmaceutical Group
Lundbeck
Matrix Laboratories
Medigen Biotechnology Corporation
Medtronic
Merck & Co.
Merck Serono
Merck Sharp & Dohme
Microport Medical
MicuRx Pharmaceuticals
Mindray
Ministry of Commerce
Ministry of Health
Ministry of Labor and Social Security
Ministry of Science and Technology
Minsheng Pharmaceutical
Mirahi Biotech
Mylan
Nanfang Hospital of Southern Medical University
Nanjing Hailing National Engineering Research Center for TCM Manufacturing Technology
Nanjing Kanghai Pharmaceutical
Nanjing Pharmaceutical
Natco Pharma
National Development and Reform Commission
Nestle
Netherlands Organization for Applied Scientific Research
NeuroVive
Newsummit Biopharma
North China Pharmaceutical Group
Northeast General Pharmaceutical
Northeast Pharmaceutical Group (NEPG)
NovaMed Pharmaceuticals
Novartis
Novast Labs
Novo Nordisk
Otsuka
Otsuka Beijing Research Institute
Ouyi Pharma
Pacific MeinuoKe
Panion & BF Biotech
Patheon
Peking University People's Hospital
Pfizer
Pharmaron
PPD
PRA
Pro Top & Mediking
Psyma Business Research China
Qilu Antibiotics
Qilu Pharmaceutical
QRxPharma
Quintiles
Regenex Corporation
Roche
S&P Pharmaceutical Industry
Sanofi
Schering-Plough
Shandong Dong-E E-Jiao
Shandong Kexing Bioproducts
Shandong Lanjin Pharmaceuticals
Shandong Luye Pharmaceutical
Shangdong Weigao Group
Shanghai BravoBio
Shanghai Celgen Bio-Pharmaceutical
Shanghai Charity Foundation
Shanghai ChemExplorer
Shanghai Clinical Research Centre
Shanghai Fosun Pharma
Shanghai Greenvalley Pharmaceutical
Shanghai Hotmed Sciences
Shanghai Institutes of Biological Sciences
Shanghai Jiao Tong University School of Medicine
Shanghai Jinhe Bio-Technology
Shanghai MengKe Pharmaceuticals
Shanghai Mental Health Center
Shanghai Pharma
Shanghai Xinshengyuan Pharmaceutical Group Medicine & Chemical Reagents Sales
Shanghai Zhangjiang Biomedical Industry Venture Capital
ShangPharma
Shantou Institute of Ultrasonic Instruments
Shenyang Sunshine
Shenzhen Kangzhe Pharmaceutical
Shenzhen Neptunus Bioengineering
Shenzhen SiBiono GeneTech
Shenzhen Wenle ('Main Luck') Pharmaceutical
Shijiazhuang Pharmaceutical Group
Shire
Sichuan Jiufeng Pharmaceutical
Sichuan Kelun Pharmaceutical
Sicor
Sihuan Pharmaceutical Holdings
Simcere Pharmaceutical
Simcere-MSD (Simcere Pharmaceutical - Merck jv)
SiniWest Holdings
Sino-American Kunming Baker Norton Pharmaceutical
Sinopharm
Sinovac Biotech
State Food and Drug Administration (SFDA)
State Key Lab of Respiratory Disease
State Population and Family Planning Commission
State Quality Control Administration
State Traditional Chinese Medicine Administration
Sumitomo Pharmaceutical (Suzhou)
Sundia Meditech
Sundiro Pharma
Sunway Biotech
Swiss Re
Symbio Pharmaceuticals
TaiGen Biotechnology
Takeda
Tangshan Yian Bioengineering
Tasly Pharmaceuticals
Teleos Healthcare
Teva Pharmaceutical Industries
The United Laboratories
Thermo Fisher Scientific
Third Affiliated Hospital, Sun Yat-Sen University
Thomas, McNerney & Partners
Tianjin International Joint Academy of Biotechnology and Medicine
Tianjin Jin Yao Group
Tianjin Medical University Cancer Hospital
Tianjin Nankai Hospital
Tianjin Pharmaceuticals Group Corporation (TJPC)
Tianjin Takeda Pharmaceuticals
Time Medical Systems
Tonghua Dongbao
Tongji University
Tongrengtang Pharmaceutical
Tsingua University
UNICEF
United Pharmatech
University of Michigan
Ventac Partners
Venturepharm Laboratories
Vertex Pharmaceuticals
Vinise Pharmaceutical
Vinise Pharmaceutical
Viva Biotech
Wanbang Biopharmaceuticals
World Customs Organisation
World Heath Organization (WHO)
World Trade Organisation
Wuhan National Bioindustry Base Construction
WuXi AppTec
Wuxi Pharma
Xiamen Amoytop Biotech
Xian-Janssen Pharmaceuticals
Yangtze River Pharmaceutical Group
Youcare Pharmaceutical Group
Yunnan Baiyao
Zensun (Shanghai) Sci & Tech
Zhejiang Beta Pharma
Zhejiang Hisun Pharmaceutical
Zhejiang Medicine
Zhejiang Tianyuan
Zhongnuo Pharmaceutical
Zhuhai United States Labs

Antibiotics: China’s Main Medicine

China is the world’s second-largest market for antibiotics, with several classes of these products sold, including penicillins, fluroquinolones, macrolides and beta-lactam antibacterials. Cephalosporins are the most popular class (see Figure 5.8). Large numbers of domestic players compete in the market; some are indicated in Table 5.8. In part this reflects an apparent tendency to mis-prescribe and over-prescribe antibiotics: 2010 research by the State Food and Drug Administration reportedly indicated that 70% of Chinese inpatients are prescribed antibiotics, while around 20% actually need them. A 2004 survey reportedly indicated that 75% of Chinese common cold sufferers would take antibiotics for the condition, despite the fact that it is virally-caused and not susceptible to antibiotic treatment. Hospitals in China have tended to over-prescribe in general, and antibiotics accounted for up to 70% of all hospital scrips as recently as five years ago. Until 2006, the over-use of antibiotics was further fuelled by the fact that the products were widely available OTC; even potent antibiotics available only for in-hospital use in countries such as the US, reports indicate. 

Curbing Antibiotics Misuse

While the widespread misuse of antibiotics has fuelled the growth of China’s pharmaceutical market, it has apparently had disastrous consequences for public health. An estimated 40% of adverse reactions to medicine recent years apparently occurred as a result of misuse of antibiotics, which also accounts for 70% of cases of hearing-impairment in China, reports suggest. The Chinese Ministry of Health reports that it has become increasingly concerned about the risk of antibacterial drug resistance to public health. Under 2011 regulations, antibacterial drugs are classified as restricted, unrestricted or special management products. Doctors who misprescribe antibiotics may lose their prescription licenses, reports indicate. Results from a study in 2010 showed that resistance rates in some bacteria are apparently as high as 80% in Chinese hospitals. 

Supplying China’s Genuine Antibiotics Needs

Increasing bacterial resistance means there is great demand for new antibacterial drugs in China, which specialist companies are attempting to meet. In October 2012, for example, MicuRx Pharmaceuticals established a joint venture (Shanghai MengKe Pharmaceuticals) with Shanghai Zhangjiang Biomedical Industry Venture Capital to develop MicuRx’s novel oxazolidinone as a treatment for Gram-positive, multidrug-resistant infections for the Chinese market.

The material was prepared in July, 2013.

LIST OF TABLES

Table 2.1 Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 2.2 Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2023
Table 2.3 Global Pharmaceutical Market by Region: Revenues ($bn), Market Shares (%), 2011
Table 2.4 Sales Channels in the Chinese Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2011
Table 2.5 Product Classes in the Chinese Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2011
Table 2.6 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2011
Table 2.7 Leading 25 Domestic Chinese Pharmaceutical Manufacturers: Revenues ($bn), Market Shares (%), 2011
Table 2.8 Leading 25 Pharma Companies Worldwide, Selected Strategic Interests in China, 2011
Table 2.9 Healthcare Reform in China: Proposed Initiatives, 2009
Table 3.1 Sales Channels in the Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 3.2 Sales Channels in the Chinese Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2016
Table 3.3 Sales Channels in the Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 3.4 Sales Channels in the Chinese Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2023
Table 3.5 Hospital Sales Channel: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 3.6 Hospital Sales Channel: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%) 2017-2023
Table 3.7 Retail Pharmacy Sales Channel: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 3.8 Retail Pharmacy Sales Channel: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%) 2017-2023
Table 3.9 Other Sales Channels: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 3.10 Other Sales Channels: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%) 2017-2023
Table 3.11 Contract Sales in China: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 3.12 Contract Sales in China: Revenues ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.1 Product Classes in the Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 4.2 Product Classes in the Chinese Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2016
Table 4.3 Product Classes in the Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 4.4 Product Classes in the Chinese Pharmaceutical Market: Revenues ($bn), Market Shares (%), 2023
Table 4.5 Pharmaceuticals Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 4.6 Pharmaceuticals Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 4.7 Pharmaceuticals Segment Breakdown: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 4.8 Pharmaceuticals Segment Breakdown: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 4.9 Biologics Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 4.10 Biologics Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%) 2017-2023
Table 4.11 Biologics Segment Breakdown: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 4.12 Biologics Segment Breakdown: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 4.13 Selected Chinese Biosimilar Manufacturers and their Activities, 2013
Table 4.14 TCM Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 4.15 TCM Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%) 2017-2023
Table 4.16 Selected TCM Manufacturers and their Activities, 2013
Table 4.17 Devices Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 4.18 Devices Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%) 2017-2023
Table 4.19 Devices Segment Breakdown: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 4.20 Devices Segment Breakdown: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 4.21 Classification of Medical Devices in China, 2013
Table 4.22 Leading Chinese Medical Device Manufacturers and their Activities, 2013
Table 5.1 Causes of Mortality in China, 2002
Table 5.2 Disease Areas Breakdown: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 5.3 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2016
Table 5.4 Disease Areas Breakdown: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 5.5 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2023
Table 5.6 Infectious Diseases Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%) 2011-2016
Table 5.7 Infectious Diseases Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 5.8 Selected Chinese Antibiotics Manufacturers and their Activities, 2013
Table 5.9 Oncology Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 5.10 Oncology Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 5.11 Selected Chinese Anticancer Drug Manufacturers and their Activities, 2013
Table 5.12 Cardiovascular Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 5.13 Cardiovascular Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 5.14 Selected Chinese Cardiovascular Drug Manufacturers and their Activities, 2013
Table 5.15 Diabetes Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 5.16 Diabetes Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 5.17 Selected Chinese Diabetes Drug Manufacturers and their Activities, 2013
Table 5.18 Respiratory Diseases Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 5.19 Respiratory Diseases Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 5.20 Autoimmune/Inflammatory Diseases Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 5.21 Autoimmune/Inflammatory Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 5.22 CNS Diseases Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 5.23 CNS Diseases Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 5.24 Other Disease Areas Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 5.25 Other Disease Areas Segment: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 6.1 Chinese Contract Manufacturing Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 6.2 Chinese Contract Manufacturing Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2023
Table 6.3 Chinese Pharma Manufacturing Output by Area: Revenues ($bn), Market Shares (%) 2011
Table 7.1 Chinese Contract Research Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
Table 7.2 Chinese Contract Research Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2023
Table 7.3 Breakdown of Chinese Contract Research Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Table 7.4 Breakdown of Chinese Contract Research Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2023
Table 7.5 Selected Chinese CROs and their Activities, 2013
Table 7.6 Domestic Chinese Companies: Selected Innovative Pharmaceutical Pipeline, 2013

Skip to top


Ask Your Question

Chinese Pharmaceutical Market 2013-2023
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: